Skip to content

Adam Byron

  • PhD
  • Research Fellow
  • University of Edinburgh
  • 19h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 2069CitationsNumber of citations received by Adam's publications. Updated daily.

Recent publications

  • A synergistic anti-cancer FAK and HDAC inhibitor combination discovered by a novel chemical-genetic high-content phenotypic screen

    • Dawson J
    • Serrels B
    • Byron A
    • et al.
    Get full text
  • Eps8 is a convergence point integrating EGFR and integrin trafficking and crosstalk

    • Paul N
    • Thomas J
    • Maldonado H
    • et al.
    Get full text

Professional experience

Research Fellow

University of Edinburgh

June 2018 - Present

Postdoctoral Research Fellow

University of Edinburgh

March 2013 - May 2018(5 years)

Visiting Research Fellow

Turun yliopisto

October 2016

Postdoctoral Research Associate

University of Manchester

November 2008 - March 2013(4 years)

Visiting Research Associate

Karolinska Institutet

January 2011 - February 2011(a month)


AstraZeneca Pharmaceuticals

September 2002 - August 2003(a year)


PhD, Biochemistry

University of Manchester

September 2004 - July 2008(4 years)

BSc (Hons) First Class, Biochemistry with Intercalated Year

University of Warwick

September 2000 - July 2004(4 years)


I am a Research Fellow at the Institute of Genetics and Molecular Medicine, University of Edinburgh. My research develops and implements proteomic approaches to investigate mechanisms of cancer cell adhesion. I received my PhD in Biochemistry from the University of Manchester, where I studied cell adhesion in the research group of Professor Martin Humphries, and where I stayed to undertake postdoctoral work. Here, I developed methodologies for the isolation and proteomic analysis of integrin adhesion complexes, which led to the description of the first experimentally defined integrin proteomes and insight into the complexity of the molecular machinery of cell adhesion. I moved to the laboratory of Professor Margaret Frame at the University of Edinburgh, where I used integrative 'omic approaches to investigate the dysregulation of cell adhesion proteins in cancer. Prior to my PhD, I studied Biochemistry at the University of Warwick, where I was awarded both Biochemistry Prizes and was selected to spend an Intercalated Year of my degree working at AstraZeneca. I am a Member of the Royal Society of Biology, the British Society for Proteome Research, the British Society for Matrix Biology, the British Society for Cell Biology and an Early Career Member of the Biochemical Society. I received the 2009 Early Career Investigator Award from the British Society for Proteome Research and the 2010 Young Investigator Award from the British Society for Matrix Biology. In 2013, I was awarded Chartered Biologist status by the Royal Society of Biology and Associate Fellowship of the Higher Education Academy.


Co-authors (130)